300583-37-3

Basic information

• Product Name: Phosphonic acid, [(4-bromophenyl)methyl]-, bis(1,1-dimethylethyl) ester
• Synonyms: di-tert-butyl p-bromobenzylphosphonate;4-bromobenzyl phosphonic acid di-tert-butyl ester
• CAS NO: 300583-37-3
• Molecular Formula: C15H24BrO3P
• Molecular Weight: 363.232
• Mol File: 300583-37-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Phosphonic acid, [(4-bromophenyl)methyl]-, bis(1,1-dimethylethyl) ester(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonic acid, [(4-bromophenyl)methyl]-, bis(1,1-dimethylethyl) ester(300583-37-3)
• EPA Substance Registry System: Phosphonic acid, [(4-bromophenyl)methyl]-, bis(1,1-dimethylethyl) ester(300583-37-3)

Safety Data

• Hazardous Substances Data: 300583-37-3(Hazardous Substances Data)

Upstream product

• 13086-84-5 di-tert-butyl phosphite 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 13086-84-5 di-tert-butyl phosphite 

Downstream Products

• 350038-44-7 3-[(2E)-3-(4-{[bis(tert-butoxy)phosphono]methyl}phenyl)prop-2-enoyl]-(4S)-4-phenyl-1,3-oxazolidin-2-one 
• 350038-42-5 (3R)-3-(4-{[bis(tert-butoxy)phosphono]methyl}phenyl)pent-4-enoic acid 
• 350038-45-8 3-[(3R)-3-(4-{[bis(tert-butoxy)phosphono]methyl}phenyl)pent-4-enoyl]-(4S)-4-phenyl-1,3-oxazolidin-2-one 
• 350038-39-0 (3R)-N-{[N-((1S)-1-{N-[(2S)-2-(naphthylmethyl)pent-4-enyl]carbamoyl}-2-carbamoylethyl)carbamoyl]cyclohexyl}-3-(4-{[bis(tert-butoxy)phosphono]methyl}phenyl)pent-4-enamide 
• 300583-36-2 (3-(4-(bis(tert-butyl)phosphono)methyl)phenyl)propanoic acid 
• 300583-39-5 3-(3-(4-((bis(tert-butyl)phosphono)methyl)phenyl)propanoyl)-4(S)-benzyl-1,3-oxazolidin-2-one 
• 300583-40-8 3-(2-(S)-azido-3-(4-((bis(tert-butyl)phosphono)methyl)phenyl)propanoyl)-4(S)-benzyl-1,3-oxazolidin-2-one 
• 1009641-03-5 4-[di-(tert-butyl)phosphonomethyl]phenyl boronic acid 

Relevant articles and documents

Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain

A monocarboxylic inhibitor was designed and synthesized to disrupt the protein–protein interaction (PPI) between GRB2 and phosphotyrosine-containing proteins. Biochemical characterizations show compound 7 binds with the Src homology 2 (SH2) domain of GRB2 and is more potent than EGFR1068 phosphopeptide 14-mer. X-ray crystallographic studies demonstrate compound 7 occupies the GRB2 binding site for phosphotyrosine-containing sequences and reveal key structural features for GRB2–inhibitor binding. This compound with a –1 formal charge offers a new direction for structural optimization to generate cell-permeable inhibitors for this key protein target of the aberrant Ras-MAPK signaling cascade.

Olefin Metathesis in the Design and Synthesis of a Globally Constrained Grb2 SH2 Domain Inhibitor

(matrix presented) One drawback frequently associated with olefin metathesis-mediated peptide macrocyclization, the loss of side chain functionality at sites of ring closure, may be circumvented by incorporation of side chain functionality within the ring